Abstract：
The neurodegenerative disorders are age-related illnesses that cause the morphology or activity of neurons to deteriorate over time. Alzheimer\'s disease is the most frequent neurodegenerative illness in the long run. The rate of advancement might vary, even though it is a progressive neurological illness. Various explanations have been proposed, however the true etiology of Alzheimer\'s disease remains unclear. Most pharmacological interventions are based on the cholinergic theory, that is earliest idea. In accordance with the amyloid hypothesis, the buildup of beta-amyloid in brain regions is the primitive cause of illness. There is no proof that any one strategy is useful in avoiding Alzheimer\'s disease, though some epidemiological studies have suggested links within various modifiable variables, such as cardiovascular risk, diet and so on. Different metals like zinc, iron, and copper are naturally present in our bodies. In metal chelation therapy drugs are used to jam the metal ions from combining with other molecules in the body. Clioquinol is one of the metal chelation drugs used by researchers. Research on metal chelation is still ongoing. In the present review, we go over the latest developments in prevalence, incidence, etiology, or pathophysiology of our understanding of Alzheimer\'s disease. Additionally, a brief discussion on the development of therapeutic chelating agents and their viability as Alzheimer\'s disease medication candidates is presented. We also assess the effect of clioquinol as a potential metal chelator.
摘要：
神经退行性疾病是导致神经元的形态或活动随时间恶化的年龄相关疾病。从长远来看，阿尔茨海默病是最常见的神经退行性疾病。进步的速度可能会有所不同，尽管这是一种进行性神经系统疾病。已经提出了各种解释，然而，阿尔茨海默病的真正病因仍不清楚。大多数药物干预是基于胆碱能理论，这是最早的想法。根据淀粉样蛋白假说,β-淀粉样蛋白在大脑区域的积累是疾病的原始原因。没有证据表明任何一种策略对避免阿尔茨海默病有用，尽管一些流行病学研究提出了各种可修改变量之间的联系，比如心血管风险，饮食等等。不同的金属如锌,铁,铜自然存在于我们的身体中。在金属螯合疗法中，药物用于干扰金属离子与体内其他分子结合。Clioquinol是研究人员使用的金属螯合药物之一。关于金属螯合的研究仍在进行中。在本次审查中，我们回顾了患病率的最新发展，发病率,病因学,或我们对阿尔茨海默病的理解的病理生理学。此外,简要讨论了治疗性螯合剂的发展及其作为阿尔茨海默病候选药物的可行性。我们还评估了氯苯酚作为潜在金属螯合剂的作用。
